Status: Actively Enrolling
Do you have pancreatic, liver, or colorectal cancer? Would you like to assist in the research in the predictors of early disease diagnosis, recurrence, and overall survival?
This study proposes to measure a likely response to ASPH (aspartyl-asparginyl-B-hydroxylase) in serum and tumor tissue levels in patients with pancreatic, liver, and colorectal cancers and to measure if ASPH levels predict early disease reoccurrence and overall survival of pancreatic and hepatocellular cancer in collaboration with Dr. Kevin Charpentier, Dr. Nishit Shah, the Comprehensive Cancer Center, and Pathology at Rhode Island Hospital.
Candidates for Trial
You may qualify for this study if you:
- Have early-stage pancreatic, liver or colorectal cancer.
- Are 21 years old or older.